07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Advancell, Helsinn deal

Advancell granted Helsinn exclusive, worldwide rights to develop and commercialize ATH008. The undisclosed topical cream is in development to treat palmoplantar erythrodysesthesia syndrome (PPES) and hand-foot skin reactions (HFSR), which are painful cutaneous reactions...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Acadra acadesine regulatory update

The European Commission granted Orphan Drug designation for Advancell's Acadra acadesine to treat multiple myeloma (MM). The small molecule that induces apoptosis independent of p53 status is in preclinical testing for MM. Advancell Advanced In...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Clinical News

ATH012: Phase IIa started

Advancell and Neurotec began the European Phase IIa NeuroAdvan trial to evaluate oral NT-KO-003 in 105 patients. The companies, which are co-developing the product, plan to out-license it after completing the trial. Advancell Advanced In...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

ATH008: Phase IIb started

Advancell began a double-blind, placebo-controlled, European Phase IIb trial to evaluate twice-daily 1%, 3% and 8% ATH008 in up to 100 patients with PPES secondary to capecitabine monotherapy. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Clinical News

Acadra acadesine: Phase I/IIa data

An open-label, dose-escalation, European Phase I/IIa trial in 24 patients with relapsed or refractory CLL showed that Acadra was well tolerated and led to reductions in leukemic tumor burden. Additionally, 7 of 9 patients treated...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

Advancell Advanced In Vitro Technologies S.A., BTG deal

BTG returned to Advancell its co-development rights for Acadra acadesine in exchange for an undisclosed potential milestone and royalties. BTG, which gained rights to the nucleoside analogue as part of its 2008 acquisition of...
07:00 , May 26, 2008 |  BC Week In Review  |  Clinical News

Cyclosporine DT autoimmune data

Data from 25 patients enrolled in a proof of concept, placebo-controlled, German trial showed that topical Cyclosporine DT, applied directly to plaques for 28 days, had clinical efficacy against psoriasis. The study was conducted by...
08:00 , Jan 21, 2008 |  BioCentury  |  Finance

Ebb & Flow

Despite disappointing product sales, Genentech (NYSE:DNA) managed to beat the Street's 4Q EPS estimate by controlling costs and posting royalty revenues above expectations. Product sales rose only 1% sequentially to $2.35 billion in 4Q07 from...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Clinical News

Acadra acadesine: Phase I/II started

Protherics began an open-label, single- and multiple-ascending dose, European Phase I/II trial in up to 30 relapsed or refractory B-CLL patients. The company is co-developing Acadra with Advancell under a 2006 deal (see BioCentury, Dec....
08:00 , Dec 20, 2001 |  BC Extra  |  Company News

Advancell, DiverDrugs neuroprotectant deal

Advanced In Vitro Cell Technologies (Barcelona, Spain) and DiverDrugs (Barcelona, Spain) will collaborate on preclinical development of DiverDrugs' DD612 neuroprotectant. Advanced will contribute project management and ADMET services, while DiverDrugs is responsible for characterizing the...